Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Sets Higher Reimbursement Rates For 3D Mammography

This article was originally published in The Gray Sheet

Executive Summary

Hologic has struggled to gain market acceptance of its 3D breast tomosynthesis technologies because of the lack of reimbursement. But CMS has now delivered a long-awaited surplus rate for 3D compared to 2D scans, which is expected to boost adoption.


Related Content

iCAD Touts PMA-Approved Tool As Time-Saver For 3D Breast Assessment
Hologic’s Tomosynthesis Improves Cancer Detection Rates Of Mammography In Study


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts